Advertisement

Why Osmotica Pharmaceuticals Jumped Today

Why Osmotica Pharmaceuticals Jumped Today

On Thursday, Osmotica Pharmaceuticals (NASDAQ: OSMT) -- a small-cap biopharmaceutical company -- announced that the U.S. Food and Drug Administration (FDA) had approved Upneeq, a therapy the company developed for the treatment of acquired blepharoptosis. This approval seems to have investors excited, and it may have been the catalyst for Osmotica's shares soaring on Friday. Acquired blepharoptosis is a condition that affects a patient's upper eyelid.